Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.

Shahriar Sharif; Amer H. Zureikat; Paula M. Novelli; Charles D. Lopez; Adel Kardosh; Ki Y. Chung; Wesley B. Jones; Hassan Hatoum; Kenneth Lee Meredith; Emmanuel E. Zervos; Antonio Ucar; Ripal T Gandhi; Reza Nazemzadeh; Pashtoon Murtaza Kasi; Erik Vandestraeten; Jochen Decaestecker; Thierry Delaunoit; Charles Charles Li; Ramtin Agah; Michael J. Pishvaian

doi:10.1200/JCO.2021.39.3_SUPPL.381

Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.

Shahriar Sharif, Amer H. Zureikat, Paula M. Novelli, Charles D. Lopez, Adel Kardosh, Ki Y. Chung, Wesley B. Jones, Hassan Hatoum, Kenneth Lee Meredith, Emmanuel E. Zervos, Antonio Ucar, Ripal T Gandhi, Reza Nazemzadeh, Pashtoon Murtaza Kasi, Erik Vandestraeten, Jochen Decaestecker, Thierry Delaunoit, Charles Charles Li, Ramtin Agah, Michael J. Pishvaian

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1200/JCO.2021.39.3_SUPPL.381
State	Published - Jan 22 2021
Event	Journal of Clinical Oncology - Duration: May 1 2021 → …

Conference

Conference	Journal of Clinical Oncology
Period	5/1/21 → …

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2021.39.3_SUPPL.381License: Unspecified

Cite this

Sharif, S., Zureikat, A. H., Novelli, P. M., Lopez, C. D., Kardosh, A., Chung, K. Y., Jones, W. B., Hatoum, H., Meredith, K. L., Zervos, E. E., Ucar, A., Gandhi, R. T., Nazemzadeh, R., Kasi, P. M., Vandestraeten, E., Decaestecker, J., Delaunoit, T., Li, C. C., Agah, R., & Pishvaian, M. J. (2021). Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2021.39.3_SUPPL.381

Sharif, S, Zureikat, AH, Novelli, PM, Lopez, CD, Kardosh, A, Chung, KY, Jones, WB, Hatoum, H, Meredith, KL, Zervos, EE, Ucar, A , Gandhi, RT, Nazemzadeh, R, Kasi, PM, Vandestraeten, E, Decaestecker, J, Delaunoit, T, Li, CC, Agah, R & Pishvaian, MJ 2021, 'Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.', Journal of Clinical Oncology, 5/1/21. https://doi.org/10.1200/JCO.2021.39.3_SUPPL.381

@conference{8916065a77c54cc8b2631da0a30e8f71,

title = "Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.",

author = "Shahriar Sharif and Zureikat, {Amer H.} and Novelli, {Paula M.} and Lopez, {Charles D.} and Adel Kardosh and Chung, {Ki Y.} and Jones, {Wesley B.} and Hassan Hatoum and Meredith, {Kenneth Lee} and Zervos, {Emmanuel E.} and Antonio Ucar and Gandhi, {Ripal T} and Reza Nazemzadeh and Kasi, {Pashtoon Murtaza} and Erik Vandestraeten and Jochen Decaestecker and Thierry Delaunoit and Li, {Charles Charles} and Ramtin Agah and Pishvaian, {Michael J.}",

note = "381 Background: There is no established treatment for locally advanced pancreatic cancer (LAPC), but by utilizing the regimens approved for metastatic pancreatic cancer, hope remains for rendering tumors resectable with chemotherapy. In this context, we looked at the resection rate in patients receiving gemcitabine plus nab-paclitaxel (Gem-Nab) in a prospective trial of patients with LAPC.; Journal of Clinical Oncology ; Conference date: 01-05-2021",

year = "2021",

month = jan,

day = "22",

doi = "10.1200/JCO.2021.39.3_SUPPL.381",

language = "American English",

}

TY - CONF

T1 - Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.

AU - Sharif, Shahriar

AU - Zureikat, Amer H.

AU - Novelli, Paula M.

AU - Lopez, Charles D.

AU - Kardosh, Adel

AU - Chung, Ki Y.

AU - Jones, Wesley B.

AU - Hatoum, Hassan

AU - Meredith, Kenneth Lee

AU - Zervos, Emmanuel E.

AU - Ucar, Antonio

AU - Gandhi, Ripal T

AU - Nazemzadeh, Reza

AU - Kasi, Pashtoon Murtaza

AU - Vandestraeten, Erik

AU - Decaestecker, Jochen

AU - Delaunoit, Thierry

AU - Li, Charles Charles

AU - Agah, Ramtin

AU - Pishvaian, Michael J.

N1 - 381 Background: There is no established treatment for locally advanced pancreatic cancer (LAPC), but by utilizing the regimens approved for metastatic pancreatic cancer, hope remains for rendering tumors resectable with chemotherapy. In this context, we looked at the resection rate in patients receiving gemcitabine plus nab-paclitaxel (Gem-Nab) in a prospective trial of patients with LAPC.

PY - 2021/1/22

Y1 - 2021/1/22

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.381

U2 - 10.1200/JCO.2021.39.3_SUPPL.381

DO - 10.1200/JCO.2021.39.3_SUPPL.381

M3 - Presentation

T2 - Journal of Clinical Oncology

Y2 - 1 May 2021

ER -

Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.

Conference

Disciplines

Access to Document

Other files and links

Cite this